Diffuse Cutaneous Systemic Sclerosis clinical trials at UCSD
1 research study open to eligible people
open to eligible people ages 18 years and up
This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study assessing the efficacy and safety of lenabasum for the treatment of diffuse cutaneous systemic sclerosis (SSc). Approximately 354 subjects will be enrolled in this study at about 60 sites in North America, Europe, Australia, and Asia. The planned duration of treatment with study drug is 52 weeks.
La Jolla, California and other locations